| Literature DB >> 29676440 |
Gertjan J L Kaspers1,2, Denise Niewerth1, Bram A J Wilhelm3, Peggy Scholte-van Houtem4,5, Marta Lopez-Yurda6,7, Johannes Berkhof8, Jacqueline Cloos1, Valerie de Haas9, Ron A Mathôt10, Andishe Attarbaschi11, André Baruchel5,12, Eveline S de Bont13, Franca Fagioli14, Claudia Rössig15, Thomas Klingebiel16, Barbara De Moerloose17, Brigitte Nelken18, Giuseppe Palumbo19, Dirk Reinhardt5,20, Pierre-Simon Rohrlich21, Pauline Simon22, Arend von Stackelberg23, Christian Michel Zwaan4,5.
Abstract
This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3-4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.Entities:
Keywords: acute leukaemia; bortezomib; childhood leukaemia; pharmacokinetics; proteasome inhibitor
Mesh：
Substances：
Year: 2018 PMID： 29676440 DOI： 10.1111/bjh.15233
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998